Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03968419
Recruitment Status : Active, not recruiting
First Posted : May 30, 2019
Last Update Posted : May 24, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor microenvironment changes on treatment by comparing pre-, on- and post-treatment samples will be evaluated.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: canakinumab Drug: pembrolizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
Actual Study Start Date : November 5, 2019
Actual Primary Completion Date : April 20, 2022
Estimated Study Completion Date : August 18, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: canakinumab monotherapy
All patients will receive canakinumab (ACZ885) prior to surgery
Drug: canakinumab
Administered subcutaneously
Other Name: ACZ885

Experimental: canakinumab + pembrolizumab
All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery
Drug: canakinumab
Administered subcutaneously
Other Name: ACZ885

Drug: pembrolizumab
200mg administered intravenously every 3 weeks

Experimental: pembrolizumab monotherapy
All patients will receive 2 doses of pembrolizumab prior to surgery
Drug: pembrolizumab
200mg administered intravenously every 3 weeks




Primary Outcome Measures :
  1. Major Pathological Response (MPR) rate based on Central review [ Time Frame: At time of surgery (approximately 4 - 6 weeks after first dose) ]
    This will assess the rate of MPR at the time of surgery in all participants randomized to canakinumab alone and in combination with pembrolizumab arms based on central review.


Secondary Outcome Measures :
  1. Antidrug antibodies (ADA) of canakinumab [ Time Frame: Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment & then at 26, 78 and 130 days after last dose ]
    To characterize the prevalence and incidence of immunogenicity (anti-drug antibodies, ADA) of canakinumab

  2. Antidrug antibodies (ADA) of pembrolizumab [ Time Frame: Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment and then at 26 days after last dose ]
    To characterize the prevalence and incidence of immunogenicity (anti-drug antibodies, ADA) of pembrolizumab

  3. Overall response rate (ORR) per investigator assessment using RECIST v1.1 [ Time Frame: From date of randomization to date of surgery up to 6 weeks ]
    ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1

  4. Serum canakinumab concentration [ Time Frame: Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment & then at 26, 78 and 130 days after last dose ]
    To characterize the pharmacokinetics of canakinumab therapy

  5. Serum pembrolizumab concentration [ Time Frame: Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), end of infusion on Day 1 Cycle 1, at end of treatment and then at 26 days after last dose ]
    To characterize the pharmacokinetics of pembrolizumab therapy

  6. Surgical feasibility rate [ Time Frame: 4 to 6 weeks after first dose ]
    To assess the rate of the surgical feasibility

  7. MPR based on central review [ Time Frame: At time of surgery (approximately 4 - 6 weeks after first dose) ]
    This will assess the rate of MPR at the time of surgery in all participants randomized to pembrolizumab monotherapy arm based on central review.

  8. MPR based on local review [ Time Frame: At time of surgery (approximately 4 - 6 weeks after first dose) ]
    This will assess the rate of MPR at the time of surgery in all randomized participants based on local review in each treatment arm.

  9. Difference in MPR rate based on central review [ Time Frame: At time of surgery (approximately 4 - 6 weeks after first dose) ]
    This will estimate the difference in MPR and posterior probability of the difference in MPR ≥ 10% between participants randomized to canakinumab + pembrolizumab combination and pembrolizumab alone based on central review.

  10. MPR rate based on the levels of biomarkers [ Time Frame: From date of randomization to 130 days after last dose of drug ]
    Biomarkers include PD-L1, CD8, hs-CRP, hs-IL-6



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key inclusion criteria:

  • Histologically confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable for primary resection by treating surgeon, except for N2 and T4 tumors.
  • Subject must be eligible for surgery and with a planned surgical resection in approximately 4-6 weeks (after the first dose of study treatment).
  • A mandatory newly obtained tissue biopsy from primary site is required for study enrollment. An archival biopsy is also acceptable if obtained up to 5 months before first day of study treatment and if the subject did not go through antineoplastic systemic therapies between biopsy collection date and beginning of study treatment.

Note: Aspirates will not be accepted.

- Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.

Key exclusion criteria:

  • Subjects with unresectable or metastatic disease.
  • History of severe hypersensitivity reactions to monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction
  • Subjects who received prior systemic therapy (including chemotherapy, other anti-cancer therapies and any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) in the past 3 years before screening
  • Active autoimmune disease that has required systemic treatment in the past 2 years prior to randomization. Control of the disorder with replacement therapy is permitted
  • Subject with suspected or proven immunocompromised state or infections

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03968419


Locations
Layout table for location information
United States, California
UCLA Oncology Hematology
La Jolla, California, United States, 92037
United States, Kansas
University of Kansas Medical Center Neurology Dept.
Kansas City, Kansas, United States, 66160
United States, New York
SUNY - Upstate Medical University
Syracuse, New York, United States, 13210
United States, Texas
Methodist Hospital / Methodist Cancer Center
Houston, Texas, United States, 77030
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1000
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2W 1T8
France
Novartis Investigative Site
Montpellier cedex 5, Herault, France, 34059
Novartis Investigative Site
Bron, France, 69677
Novartis Investigative Site
Paris, France, 75679
Germany
Novartis Investigative Site
Bad Berka, Germany, 99437
Novartis Investigative Site
Giessen, Germany, 35392
Novartis Investigative Site
Halle (Saale), Germany, 06120
Novartis Investigative Site
Koeln, Germany, 51109
Greece
Novartis Investigative Site
Thessaloniki, Greece, 57001
Japan
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277 8577
Netherlands
Novartis Investigative Site
Breda, Netherlands, 4819 EV
Novartis Investigative Site
Hertogenbosch, Netherlands, 5200
Novartis Investigative Site
Maastricht, Netherlands, 6229 HX
Russian Federation
Novartis Investigative Site
Omsk, Russian Federation, 644013
Novartis Investigative Site
Saint Petersburg, Russian Federation, 197022
Novartis Investigative Site
St Petersburg, Russian Federation, 195271
Spain
Novartis Investigative Site
Jaen, Andalucia, Spain, 23007
Novartis Investigative Site
Oviedo, Asturias, Spain, 33011
Novartis Investigative Site
Madrid, Spain, 28034
Taiwan
Novartis Investigative Site
Taipei, Taiwan, 110
Novartis Investigative Site
Taipei, Taiwan
Turkey
Novartis Investigative Site
Izmir, Turkey
Novartis Investigative Site
Sakarya, Turkey, 54290
Novartis Investigative Site
Sihhiye / Ankara, Turkey, 06100
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03968419    
Other Study ID Numbers: CACZ885V2201C
2018-004813-42 ( EudraCT Number )
First Posted: May 30, 2019    Key Record Dates
Last Update Posted: May 24, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
ACZ885
canakinumab
pembrolizumab
NSCLC
non-small cell lung cancer
non small cell lung cancer
early stage NSCLC
squamous
non-squamous,
MPR
major pathological response
hs-CRP
PD-L1
hsCRP
surgery
neo-adjuvant
neo adjuvant
CD8
hs-IL-6
CANOPY
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents